Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

d Generation Rhu FSH in Non-Regulated Markets

• 3rd Generation Rhu FSH

• Purified Urinary Human Choriogonadotropin (hCG)

• Recombinant Human Choriogonadotropin (rhCG)

• Recombinant Human Luteinizing Hormone (rhLH)

• hCG Receptor Agonist

 

9 ) Thrombolytics & Fibrinolytics

 

• Non-fibrin selective (1st generation) Fibrinolytics

• Fibrin selective wild-type t-PA-based Fibrinolytics

• Fibrin selective engineered t-PA-based Fibrinolytics

• Non-t-PA-based Fibrinolytics

• Plasmin-based Fibrinolytics

• Adjunctive therapy to Fibrinolytics

• Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets

• Corporate Thrombolytic Product Portfolios and R&D Pipelines

 

10) Enzyme Replacement Therapies

 

• Gaucher Disease

• Fabry Disease

• Pompé Disease

• Hunter Disease (MPS II)

• Niemann Pick Diseases

• Mucopolysaccharidosis I (MPS I)

• San Filippo Syndrome (MPS IIIA)

• Morquio Syndrome (MPS IVA)

• Mucopolysaccharidosis VI (MPS VI)

• Tay-Sachs Disease

• Chronic Deficiency of Adenosine Deaminase

• Phenylketonuria / Hyperphenylalaninemia

• Other Enzyme Replacement Therapies

• Exocrine Pancreatic Insufficiency: Porcine-Derived ERT

• Exocrine Pancreatic Insufficiency: Recombinant ERT

• Others

 

 

 

To order this report:

Biopharmaceutical Industry:

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... DIEGO , July 28, 2015  Kerastem Technologies ... approval from the U.S. FDA Center For Biologics Evaluation ... Therapies to conduct a clinical trial investigating the safety ... of female and early male pattern baldness (androgenic alopecia). ... STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... N.C., July 28, 2015  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2015. ... compared to the second quarter of 2014 when ... Ph.D., United Therapeutics, President and Co-Chief Executive Officer. ... an increase in the number of patients being ...
(Date:7/27/2015)... EDMONTON , July 27, 2015 /PRNewswire/ - Quest ... pharmaceutical company developing and commercializing products for the treatment ... Quest announces that it has closed a $1,000,000 ... private placement of 16,666,667 units of the Company at ... comprised of one common share and one common share ...
(Date:7/27/2015)... 2015 Research presented at the 2015 AACC ... the studies that led to a fingerprick Ebola test ... disease to receive approval from the World Health Organization ... grip on West Africa by ... workers to isolate and treat these patients much faster ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Quest PharmaTech Closes $1,000,000 Private Placement 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... Calif., Feb. 4 Arryx, Inc.,announced the addition ... Holographic Optical Trapping ("HOT") product line. The HOTkit,Complete ... events, and now, through the power of light, ... The HOTkit Complete was unveiled February 4 ...
... HORSHAM, Pa., Feb. 4 Centocor, Inc. announced ... (CNTO 1275),has been accepted for review by the ... of adult patients with chronic moderate to severe ... with a novel,mechanism of action that targets the ...
... HAVEN, Conn., Feb. 4 VION,PHARMACEUTICALS, INC. (Nasdaq: ... the Company,s senior management team as Vice President,Medical., ... pleased,to have Bill Hahne joining Vion in medical affairs. ... will be extremely useful to our,efforts to file a ...
Cached Biology Technology:Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 2Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 3Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 2Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 3
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Americans may not be getting enough calcium in their ... 2011 issue of the Journal of the American Dietetic ... calcium intake in the US population because both dietary and ... to accompanying patterns in energy intake. "Calcium plays a ...
... urban communities, less than 1 in 100 inhabitants died from ... 9 out of 10 died. An important explanation for the ... decades before the Spanish flu came. Those living in urban ... protected against illness and death in 1918 than those living ...
... detecting the early stages of a major cause of failure ... and perhaps avoid additional surgery. More than 1.5 million total ... success rate is 90 per cent, almost 10 per cent ... the ACS journal Molecular Pharmaceutics . Dong Wang ...
Cached Biology News:Americans still may not be getting enough calcium 2Americans still may not be getting enough calcium 3Large differences in mortality between urban and isolated rural areas 2Large differences in mortality between urban and isolated rural areas 3
... XpressPack Luminescent Detection System is intended for ... DNA generated by an in-house validated method ... a selected target of interest. ... System is a hybridization capture assay designed ...
... System is optimized for maximum packaging efficiencies of ... bacteriophage l vector. Using a test insert with ... arms (> 4 x 10^8 pfu/g ligated l ... is extremely easy to use; simply add up ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: